Q-omics provides the consensus-scored PRKCZ profile across patient tissues and cancer cell-line models. PRKCZ expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PRKCZ is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, PRKCZ protein abundance shows 29,417 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, BLCA, and GBM as cancer lineages where PRKCZ shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKCZ — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKCZ survival associations across molecular data types. PRKCZ RNA expression shows survival associations in the most cancer types (21), followed by mutation status (5) and mass-spec protein abundance (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKCZ RNA expression–survival associations across cancer types. High PRKCZ expression shows unfavorable associations in ACC, but favorable associations in KIRC, MESO, UVM, LUAD and SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PRKCZ RNA expression.
This table summarizes PRKCZ tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 11. The strongest signals are observed in BLCA for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRKCZ. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKCZ shows lower tumor expression in KICH, LUAD, LUSC and KIRC and higher tumor expression in BLCA and UCEC. The BLCA box plot shows higher PRKCZ RNA expression in tumor versus normal tissue (log2 FC = +2.097, t-test p < 0.001).
This table shows molecular features associated with PRKCZ in patient tissues and cancer cell lines. In patient samples, PRKCZ shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKCZ RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and UPPER_AERODIGESTIVE_TRACT.
